Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-00489791 Dose-Response in PAH
NCT00853112Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Apr 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of PF-00489791 in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Started Apr 2009; status: terminated.
02
Drugs
PF-00489791
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00853112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00853112.